Kowa Kowabo Company, Ltd.

Global Strategy

Kowa's pharmaceutical business is global, with offices in the United States, Europe and Asia. With a commitment to ground-breaking research, development and marketing, we ensure steady supply of products with quality and reliability to help people around the world enjoy better health.
Livalo® is a ethical drug for the treatment of dyslipidemia developed in Japan by Kowa and with its proven efficacy it has grown into our global product currently marketed in the United States and Asia.
Further launches are expected in Europe and other regions in the near future.

USA

Kowa Research Institute, Inc.

Kowa Research Institute, Inc.

Research and development

Center for Interdisciplinary Cardiovascular Sciences

Center for Interdisciplinary Cardiovascular Sciences

Research

Europe

Kowa Pharmaceutical Europe AG

Kowa Pharmaceutical Europe AG

Administration center, Research and development

Asia

Kowa Pharmaceutical Asia Pte. Ltd.

Kowa Pharmaceutical Asia Pte. Ltd.

Administration center, Research and development

Kowa Pharmaceuticals (China) Co., Ltd.

Kowa Pharmaceuticals (China) Co., Ltd.

Sales and marketing, Manufacture

Kowa Korea Company, Ltd.

Kowa Korea Company, Ltd.

Sales and marketing

Kowa Taiwan Tsusho Co., Ltd.

Kowa Taiwan Tsusho Co., Ltd.

Sales and marketing

Kowa (Thailand) Co., Ltd.

Kowa (Thailand) Co., Ltd.

Sales and marketing